Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

DLL3 / SCDO1 Antibody [DLL3/9361]

In Stock
Catalog Number Formulation Size Price
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes


This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Mutations in this gene cause autosomal recessive spondylocostal dysostosis 1. Two transcript variants encoding distinct isoforms have been identified for this gene.

Product Properties & Targets

Antibody Type
Species Reactivity
Isotype / Light Chain
IgG2c / Kappa
Cellular Localization
Cell surface, Membrane
Gene Name
Positive Control
Human small cell lung cancer or brain.
Recombinant fragment (around aa400-618) of human DLL3 protein (exact sequence is proprietary)
Alternate Names
delta-like protein 3, Delta Drosophila like 3 antibody; Delta like 3 Drosophila antibody; Delta like 3 homolog Drosophila antibody; Delta like 3 protein antibody; Delta like protein 3 precursor antibody; Delta-like protein 3 antibody; Delta3 antibody; Dll3 antibody; DLL3_HUMAN antibody; Drosophila Delta homolog 3 antibody; SCDO1 antibody; SCOD1 antibody; Spondylocostal dysostosis autosomal recessive antibody, SCDO1

Database Links

Entrez Gene ID

Additional Information

Chromosome Location
Mol. Weight of Antigen


  • Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm.

Key References

  • Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12(1):61. Published 2019 Jun 18. doi:10.1186/s13045-019-0745-2
  • Chou J, Egusa EA, Wang S, et al. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023;83(2):301-315. doi:10.1158/0008-5472.CAN-22-1433
  • Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16(1):66. Published 2023 Jun 24. doi:10.1186/s13045-023-01464-y
  • Jaspers JE, Khan JF, Godfrey WD, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9):e166028. Published 2023 May 1. doi:10.1172/JCI166028

Storage & Stability

Antibody with azide - store at 4 to 8°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

Antibody Purified from Bioreactor Concentrate by Protein A/G and conjugated to various reporter molecules. Prepared in 10mM PBS with 0.05% BSA and 0.05% azide. Contact us if you require this Ab in a different format.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “DLL3 / SCDO1 Antibody”

Your email address will not be published. Required fields are marked *


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.